ABSTRACT
Objective Through the detection of MIP-1α and VEGF levels in serum and CSF of ALS patients, we evaluated the clinical value of MIP-1 and VEGF levels in ALS patients. Methods A total of 80 patients with ALS were collected from Kuangwu Hospital of Tongchuanin from Jan, 2012 to Jun, 2015, and 67 patients with non-inflammation neurological diseases were chosen as control group. We obtained CSF and serum samples,and the MIP-1α and VEGF levels were measured by ELISA method. Results The MIP-1α levels in serum and CSF of ALS patients were statistically and significantly higher than those in the control group (P＜0.05) . The VEGF levels in serum of ALS patients were statistically and significantly higher than those in the control group (P＜0.05).The VEGF levels in CSF of ALS patients were not higher than those in the control group,statistically insignificant (P＞0.05).MIP-1 alpha and VEGF levels was positively correlated with ALS course. The MIP-1αand VEGF levels of the long duration group were greater than the short duration group (P＜0.05) . Conclusion The rising of MIP-1α and VEGF may indicate an activation of compensatory responses in ALS which suggested that MIP-1 alpha and VEGF are involved in the pathophysiology of amyotrophic lateral sclerosis. We propose that MIP-1α and VEGF may be a useful biomarker witha prognostic and evaluating potential for ALS.